• Login
    View Item 
    •   Mak IR Home
    • College of Health Sciences (CHS)
    • School of Health Sciences (Health-Sciences)
    • School of Health Sciences (Health-Sciences) Collections
    • View Item
    •   Mak IR Home
    • College of Health Sciences (CHS)
    • School of Health Sciences (Health-Sciences)
    • School of Health Sciences (Health-Sciences) Collections
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    A novle polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single dose efavirenz population pharmacokinetics in Ugandans

    Thumbnail
    View/Open
    Journal Article (874.9Kb)
    Date
    2009
    Author
    Mukonzo, Jackson K
    Röshammar, Daniel
    Waako, Paul
    Andersson, Maria
    Fukasawa, Takashi
    Milani, Lili
    Svensson, Jan Olof
    Ogwal-Okeng, Jasper
    Gustafsson, Lars L.
    Aklillu, Eleni
    Metadata
    Show full item record
    Abstract
    AIMS Efavirenz exhibits pharmacokinetic variability causing varied clinical response. The aim was to develop an integrated population pharmacokinetic/pharmacogenetic model and investigate the impact of genetic variations, sex, demographic and biochemical variables on single-dose efavirenz pharmacokinetics among Ugandan subjects, using NONMEM. METHODS Efavirenz plasma concentrations (n = 402) from 121 healthy subjects were quantified by high-performance liquid chromatography. Subjects were genotyped for 30 single nucleotide polymorphisms (SNPs), of which six were novel SNPs in CYP2B6, CYP3A5 and ABCB1. The efavirenz pharmacokinetics was described by a two-compartment model with zero- followed by first-order absorption. RESULTS Apparent oral clearance (95% confidence interval) was 4 l h l-1 (3.5, 4.5) in extensive metabolizers. In the final model, incorporating multiple covariates, statistical significance was found only for CYP2B6*6 and CYP2B6*11 on apparent oral clearance as well as ABCB1 (rs3842) on the relative bioavailability. Subjects homozygous for CYP2B6*6 (G516T, A785G) and *11 displayed 21 and 20% lower apparent oral clearance, respectively. Efavirenz relative bioavailability was 26% higher in subjects homozygous for ABCB1 (rs3842). The apparent peripheral volume of distribution was twofold higher in women compared with men. CONCLUSIONS The model identified the four factors CYP2B6*6, CYP2B6*11, a novel variant allele in ABCB1 (rs3842) and sex as major predictors of efavirenz plasma exposure in a healthy Ugandan population after single-dose administration. Use of mixed-effects modelling allowed the analysis and integration of multiple pharmacogenetic and demographic covariates in a pharmacokinetic population model.
    URI
    http://hdl.handle.net/10570/1600
    Collections
    • School of Health Sciences (Health-Sciences) Collections

    DSpace 5.8 copyright © Makerere University 
    Contact Us | Send Feedback
    Theme by 
    Atmire NV
     

     

    Browse

    All of Mak IRCommunities & CollectionsTitlesAuthorsBy AdvisorBy Issue DateSubjectsBy TypeThis CollectionTitlesAuthorsBy AdvisorBy Issue DateSubjectsBy Type

    My Account

    LoginRegister

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    DSpace 5.8 copyright © Makerere University 
    Contact Us | Send Feedback
    Theme by 
    Atmire NV